The U.S. Food and Drug Administration (FDA) has announced an extension of its acceptance period for E2B(R2)-formatted Individual Case Safety Reports (ICSRs) through 30 September 2026, providing additional flexibility for organizations that have not yet completed their transition to the E2B(R3) standard.
The extension is intended to support Marketing Authorization Holders (MAHs), pharmaceutical companies, and pharmacovigilance service providers as they continue upgrading safety systems, validating data mappings, and implementing E2B(R3)-compliant reporting processes. While the FDA will continue to accept E2B(R2) submissions during this period, organizations that have already transitioned to E2B(R3) are expected to continue using the newer format for future submissions.
E2B(R3) remains the global standard for electronic transmission of safety reports, enabling improved data quality, interoperability, and regulatory review efficiency. The FDA’s decision provides additional time for industry stakeholders to address technical and operational challenges; however, companies are encouraged to use this extension strategically to complete system validation, testing, and compliance readiness activities ahead of the revised deadline.
Select Mandate HA
Select Mandate Function